PMID- 31561282
OWN - NLM
STAT- MEDLINE
DCOM- 20210615
LR  - 20210615
IS  - 1749-4486 (Electronic)
IS  - 1749-4478 (Print)
IS  - 1749-4478 (Linking)
VI  - 45
IP  - 1
DP  - 2020 Jan
TI  - Standardised Ki-67 proliferation index assessment in early-stage laryngeal 
      squamous cell carcinoma in relation to local control and survival after primary 
      radiotherapy.
PG  - 12-20
LID - 10.1111/coa.13449 [doi]
AB  - OBJECTIVES: Ambiguous results have been reported on the predictive value of the 
      Ki-67 proliferation index (Ki-67 PI) regarding local control (LC) and survival 
      after primary radiotherapy (RT) in early-stage laryngeal squamous cell cancer 
      (LSCC). Small study size, heterogenic inclusion, variations in immunostaining and 
      cut-off values are attributing factors. Our aim was to elucidate the predictive 
      value of the Ki-67 PI for LC and disease-specific survival (DSS) using a 
      well-defined series of T1-T2 LSCC, standardised automatic immunostaining and 
      digital image analysis (DIA). METHODS: A consecutive and well-defined cohort of 
      208 patients with T1-T2 LSCC treated with primary RT was selected. The Ki-67 PI 
      was determined using DIA. Mann-Whitney U-tests, logistic and Cox regression 
      analyses were performed to assess associations between Ki-67 PI, 
      clinicopathological variables, LC and DSS. RESULTS: In multivariate Cox 
      regression analysis, poor tumour differentiation (HR 2.20; 95% CI 1.06-4.59, 
      P = .04) and alcohol use (HR 2.84, 95% CI 1.20-6.71; P = .02) were independent 
      predictors for LC. Lymph node positivity was an independent predictor for DSS (HR 
      3.16, 95% CI 1.16-8.64; P = .03). Ki-67 PI was not associated with LC (HR 1.59; 
      95% CI 0.89-2.81; P = .11) or DSS (HR 0.98; 95% CI 0.57-1.66; P = .97). In 
      addition, continuous Ki-67 PI was not associated with LC (HR 2.03; 95% CI 
      0.37-11.14, P = .42) or DSS (HR 0.62; 95% CI 0.05-8.28; P = .72). CONCLUSION: The 
      Ki-67 PI was not found to be a predictor for LC or DSS and therefore should not 
      be incorporated in treatment-related decision-making for LSCC.
CI  - (c) 2019 The Authors. Clinical Otolaryngology published by John Wiley & Sons Ltd.
FAU - Kop, Emiel
AU  - Kop E
AUID- ORCID: 0000-0001-5731-4439
AD  - Department of Otorhinolaryngology, University Medical Center Groningen, 
      Groningen, The Netherlands.
FAU - de Bock, Geertruida H
AU  - de Bock GH
AUID- ORCID: 0000-0003-3104-4471
AD  - Department of Epidemiology, University of Groningen, University Medical Hospital 
      Groningen, Groningen, The Netherlands.
FAU - Noordhuis, Maartje G
AU  - Noordhuis MG
AUID- ORCID: 0000-0002-4448-4700
AD  - Department of Otorhinolaryngology, University Medical Center Groningen, 
      Groningen, The Netherlands.
FAU - Slagter-Menkema, Lorian
AU  - Slagter-Menkema L
AD  - Department of Otorhinolaryngology, University Medical Center Groningen, 
      Groningen, The Netherlands.
FAU - van der Laan, Bernard F A M
AU  - van der Laan BFAM
AUID- ORCID: 0000-0002-5016-2871
AD  - Department of Otorhinolaryngology, University Medical Center Groningen, 
      Groningen, The Netherlands.
FAU - Langendijk, Johannes A
AU  - Langendijk JA
AUID- ORCID: 0000-0003-1083-372X
AD  - Department of Radiotherapy, University of Groningen, University Medical Hospital 
      Groningen, Groningen, The Netherlands.
FAU - Schuuring, Ed
AU  - Schuuring E
AUID- ORCID: 0000-0003-3655-143X
AD  - Department of Pathology & Medical Biology, University of Groningen, University 
      Medical Hospital Groningen, Groningen, The Netherlands.
FAU - van der Vegt, Bert
AU  - van der Vegt B
AUID- ORCID: 0000-0002-2613-1506
AD  - Department of Pathology & Medical Biology, University of Groningen, University 
      Medical Hospital Groningen, Groningen, The Netherlands.
LA  - eng
PT  - Journal Article
DEP - 20191105
PL  - England
TA  - Clin Otolaryngol
JT  - Clinical otolaryngology : official journal of ENT-UK ; official journal of 
      Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery
JID - 101247023
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Ki-67 Antigen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/metabolism
MH  - Biopsy
MH  - Carcinoma, Squamous Cell/*metabolism/mortality/radiotherapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunohistochemistry
MH  - Ki-67 Antigen/*metabolism
MH  - Laryngeal Neoplasms/*metabolism/mortality/radiotherapy
MH  - Male
MH  - Middle Aged
MH  - *Neoplasm Staging
MH  - Netherlands/epidemiology
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate/trends
MH  - Time Factors
PMC - PMC6973088
OTO - NOTNLM
OT  - Ki-67
OT  - disease-specific survival
OT  - head and neck cancer
OT  - laryngeal carcinoma
OT  - local control
OT  - proliferation
OT  - radiotherapy
COIS- None to declare.
EDAT- 2019/09/29 06:00
MHDA- 2021/06/16 06:00
PMCR- 2020/01/21
CRDT- 2019/09/28 06:00
PHST- 2019/07/04 00:00 [received]
PHST- 2019/09/08 00:00 [accepted]
PHST- 2019/09/29 06:00 [pubmed]
PHST- 2021/06/16 06:00 [medline]
PHST- 2019/09/28 06:00 [entrez]
PHST- 2020/01/21 00:00 [pmc-release]
AID - COA13449 [pii]
AID - 10.1111/coa.13449 [doi]
PST - ppublish
SO  - Clin Otolaryngol. 2020 Jan;45(1):12-20. doi: 10.1111/coa.13449. Epub 2019 Nov 5.